organization · Reporting owner
Quaker BioVentures II LP
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
TELA Bio, Inc.
Report date June 02, 2022 · Filed June 23, 2022
Jointly reported with Quaker BioVentures Capital II, L.P.
Section 16 reporting ended · disclosed 2022-06-23. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-06-02 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2022-06-02 · Other · Disposed 1,751,100 · Balance 0 F1: Quaker BioVentures II, L.P. distributed these shares on a pro rata basis, for no consideration. F2: Quaker BioVentures Capital II, L.P., the general partner of Quaker BioVentures II, L.P., received its pro rata shares in the distribution and in turn distributed all such shares to its own partners. |
Filing footnotes · ownership attribution and instrument terms
F1: Quaker BioVentures II, L.P. distributed these shares on a pro rata basis, for no consideration.
F2: Quaker BioVentures Capital II, L.P., the general partner of Quaker BioVentures II, L.P., received its pro rata shares in the distribution and in turn distributed all such shares to its own partners.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 02, 2022 Filed Jun 23, 2022 06:30 UTC | TELA Bio, Inc. TELA · Entity 7381 | OtherCommon Stock | 1,751,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-073703 · tm2219007-1_4seq.xml · nonDerivative · entry 1 Quaker BioVentures II LP · CIK 0001497725 · 10% owner Quaker BioVentures Capital II, L.P. · CIK 0001583083 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Quaker BioVentures II, L.P. distributed these shares on a pro rata basis, for no consideration. F2 · balance_after: Quaker BioVentures Capital II, L.P., the general partner of Quaker BioVentures II, L.P., received its pro rata shares in the distribution and in turn distributed all such shares to its own partners. Read SEC document |
| November 13, 2019 Filed Nov 13, 2019 21:03 UTC | TELA Bio, Inc. TELA · Entity 7381 | ConversionWarrant (right to buy) · Derivative | 446,813 | $0.00 Strike: $28.65 | $0.00 |
DisclosureSEC source: 0001192482-19-000430 · edgar.xml · derivative · entry 7 Quaker BioVentures II LP · CIK 0001497725 · 10% owner Quaker BioVentures Capital II, L.P. · CIK 0001583083 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 446,813 Underlying: Common Stock · 18,096 shares Expires 2027-01-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · kind: Warrants exercisable for shares of Series B Preferred Stock automatically converted into warrants exercisable for shares of Common Stock upon the closing of the Issuer's initial public offering. Read SEC document |
| November 13, 2019 Filed Nov 13, 2019 21:03 UTC | TELA Bio, Inc. TELA · Entity 7381 | ConversionWarrant (right to buy) · Derivative | 446,813 | $0.00 Strike: $1.16 | $0.00 |
DisclosureSEC source: 0001192482-19-000430 · edgar.xml · derivative · entry 6 Quaker BioVentures II LP · CIK 0001497725 · 10% owner Quaker BioVentures Capital II, L.P. · CIK 0001583083 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Series B Preferred Stock · 446,813 shares Expires 2027-01-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · kind: Warrants exercisable for shares of Series B Preferred Stock automatically converted into warrants exercisable for shares of Common Stock upon the closing of the Issuer's initial public offering. Read SEC document |
| November 13, 2019 Filed Nov 13, 2019 21:03 UTC | TELA Bio, Inc. TELA · Entity 7381 | ConversionSeries B Preferred Stock · Derivative | 12,763,434 | $0.00 | $0.00 |
DisclosureSEC source: 0001192482-19-000430 · edgar.xml · derivative · entry 5 Quaker BioVentures II LP · CIK 0001497725 · 10% owner Quaker BioVentures Capital II, L.P. · CIK 0001583083 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 516,947 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. F3 · derivative.exercise_date: Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. F3 · derivative.expiration_date: Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. F4 · derivative.underlying_shares: Reflects 1-for-24.69 reverse stock split which became effective on October 28, 2019. Read SEC document |
| November 13, 2019 Filed Nov 13, 2019 21:03 UTC | TELA Bio, Inc. TELA · Entity 7381 | ConversionSeries A Preferred Stock · Derivative | 8,530,145 | $0.00 | $0.00 |
DisclosureSEC source: 0001192482-19-000430 · edgar.xml · derivative · entry 4 Quaker BioVentures II LP · CIK 0001497725 · 10% owner Quaker BioVentures Capital II, L.P. · CIK 0001583083 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 345,489 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Shares of Series A Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. F2 · derivative.exercise_date: Shares of Series A Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. F2 · derivative.expiration_date: Shares of Series A Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. F4 · derivative.underlying_shares: Reflects 1-for-24.69 reverse stock split which became effective on October 28, 2019. Read SEC document |
| November 13, 2019 Filed Nov 13, 2019 21:03 UTC | TELA Bio, Inc. TELA · Entity 7381 | ConversionCommon Stock | 516,947 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001192482-19-000430 · edgar.xml · nonDerivative · entry 3 Quaker BioVentures II LP · CIK 0001497725 · 10% owner Quaker BioVentures Capital II, L.P. · CIK 0001583083 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,751,100 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. Read SEC document |
| November 13, 2019 Filed Nov 13, 2019 21:03 UTC | TELA Bio, Inc. TELA · Entity 7381 | ConversionCommon Stock | 345,489 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001192482-19-000430 · edgar.xml · nonDerivative · entry 2 Quaker BioVentures II LP · CIK 0001497725 · 10% owner Quaker BioVentures Capital II, L.P. · CIK 0001583083 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,234,153 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Shares of Series A Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. Read SEC document |
| November 08, 2019 Filed Nov 13, 2019 21:03 UTC | TELA Bio, Inc. TELA · Entity 7381 | PurchaseCommon Stock | 153,846 | $13.00 | $1,999,998.00 |
DisclosureSEC source: 0001192482-19-000430 · edgar.xml · nonDerivative · entry 1 Quaker BioVentures II LP · CIK 0001497725 · 10% owner Quaker BioVentures Capital II, L.P. · CIK 0001583083 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 888,664 F1 · balance_after: Reflects 705,530 shares of common stock received by the reporting person as a payment-in-kind dividend on Series A Preferred Stock and Series B Preferred Stock exempt from reporting under Rule 16a-9(a). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.